BCMA means B-Cell Maturation Antigen.
BCMA means the receptor described in International Patent ---- Application [*].
BCMA or the “Administrator” shall mean the British Columbia Medical Association as administrator of the BCMA Health Benefits Trust Fund;
Examples of BCMA in a sentence
BCMA is essential for the survival of long-lived bone marrow plasma cells.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1).
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease.
APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity.
More Definitions of BCMA
BCMA means the specific Antigen (or part thereof) coded for by reference to the sequence defined in Schedule 1 under the BCMA-CAR Program; EXHIBIT 10.1 ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(B)(4) and 230.406 “[***]” means [***] in which one of the [***] intended to [***] on the [***] is capable of binding to [***]; “[***] Option” means Autolus’s rights under Clause 7; “[***] Field” means all uses without restriction except for use in [***];
BCMA means an agreement between the Company, Cowen and Chardan, entered into on or about December 7, 2017.
BCMA means British Columbia Medical Association;
BCMA means the specific Antigen (or part thereof) coded for by reference to the sequence defined in Schedule 1 under the BCMA-CAR Program;
BCMA means that certain protein known as “B-cell maturation antigen”, which is also known as “TNFRSF17”.
BCMA means B-cell maturation antigen. 1.8 “Belamaf” has the meaning set forth in the Recitals hereto. 1.9 “Bioanalytical Testing” has the meaning set forth in Section 9.3. 1.10 “Biomarkers” mean any naturally occurring molecule, gene or characteristic by which a particular pathological or physiological process can be identified and serially monitored during a therapeutic intervention, including blood (including cells, RNA and circulating multiple myeloma cells (CMMCs)), serum (including cytokines and sBCMA), plasma (including cfDNA), tissue and tumors (including FFPE bone marrow aspirate and biopsy Samples). 1.11 “Biomarker Testing” has the meaning set forth in Section 9.2. 1.12 “Business Day” means any day other than (a) a Saturday, Sunday or any public holiday in Boston, Massachusetts or London, England; and (b) a day falling within the time period from and including 24 December up to and including 1 January. 1.13 “cGMP” means the current Good Manufacturing Practices officially published and interpreted by EMA, FDA and other applicable Regulatory Authorities that may be in effect from time to time and are applicable to the Manufacture of the Compounds. These include requirements set forth in FDA’s regulations at 21 CFR Parts 11, 210, 211 and 600, as applicable to the processing, manufacture, handling, receipt, packaging, labelling, release and distribution of products and services subject to this Agreement. 1.14 “Change of Control” of a Party means any of the following, in a single transaction or a series of related transactions: (a) the sale or disposition of all or substantially all of the assets of such Party to a Third Party, (b) the direct or indirect acquisition by a Third Party (other than an employee benefit plan (or related trust) sponsored or maintained by such Party or any of its Affiliates) of beneficial ownership of more than fifty percent (50%) of
BCMA means that specific protein known as B-cell maturation antigen or tumor necrosis factor receptor superfamily member 17 (TNFRSF17) or CD269 in addition to any other known aliases [***].